Role of activated nuclear factor-κB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck

被引:90
作者
Allen, Clint T. [1 ]
Ricker, Justin L. [1 ]
Chen, Zhong [1 ]
Van Waes, Carter [1 ]
机构
[1] Natl Inst Deafness & Other Commun Disorders, Head & Neck Surg Branch, NIH, Bethesda, MD 20892 USA
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2007年 / 29卷 / 10期
关键词
nuclear factor-kappa B; signal transduction; head and neck squamous cell carcinoma; bortezomib; EGFR;
D O I
10.1002/hed.20615
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. Nuclear factor-kappa B (NF-kappa B), a transcription factor known to modulate expression of factors involved in inflammation, immunity, proliferation, and apoptosis, is constitutively activated and plays a role in pathogenesis and therapeutic resistance in head and neck squamous cell carcinoma (HNSCC). Understanding the molecular alterations leading to aberrant NF-kappa B activation in HNSCC may direct investigators to novel therapeutic targets. Methods. Results of laboratory and clinical studies are reviewed. Results. The structure, function, and activation of NF-kappa B, products of NF-kappa B target genes and their role in HNSCC oncogenesis, and current NF-kappa B modulating interventions are described. Conclusions. Aberrant NF-kappa B activation contributes to the expression of oncogenes and the malignant phenotype observed in HNSCC. NF-kappa B, along with providing a link between cancer and inflammation, may serve as an appropriate therapeutic target to inhibit tumor growth and sensitize cancer cells to established cytotoxic anticancer therapies. (c) 2007 Wiley Periodicals, Inc.
引用
收藏
页码:959 / 971
页数:13
相关论文
共 117 条
[1]  
Adams J, 1999, CANCER RES, V59, P2615
[2]  
Andela VB, 2000, CANCER RES, V60, P6557
[3]  
[Anonymous], ONCOLOGY WILLISTON P
[4]  
[Anonymous], ONCOLOGY WILLISTON P
[5]   Cigarette smoke condensate activates nuclear transcription factor-κB through phosphorylation and degradation of IκBα:: correlation with induction of cyclooxygenase-2 [J].
Anto, RJ ;
Mukhopadhyay, A ;
Shishodia, S ;
Gairola, CG ;
Aggarwal, BB .
CARCINOGENESIS, 2002, 23 (09) :1511-1518
[6]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[7]   Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines [J].
Bancroft, CC ;
Chen, Z ;
Yeh, J ;
Sunwoo, JB ;
Yeh, NT ;
Jackson, S ;
Jackson, C ;
Van Waes, C .
INTERNATIONAL JOURNAL OF CANCER, 2002, 99 (04) :538-548
[8]  
Bancroft CC, 2001, CLIN CANCER RES, V7, P435
[9]   Control of apoptosis by Rel/NF-κB transcription factors [J].
Barkett, M ;
Gilmore, TD .
ONCOGENE, 1999, 18 (49) :6910-6924
[10]  
BARTKOVA J, 1995, CANCER RES, V55, P949